Teva nabs experimental Tourette drug in $700M Emalex buyout
Summary
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s...
Description
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source